MCID: TRN018
MIFTS: 52

Transitional Cell Carcinoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 50 14
Carcinoma, Transitional Cell 42 69
Transitional Cell Neoplasm 12 69
Transitional Cell Carcinoma of Bladder 69
Carcinoma Transitional Cell 52
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2671
MeSH 42 D002295
NCIt 47 C2930 C6783

Summaries for Transitional Cell Carcinoma

Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to infiltrating ureter transitional cell carcinoma and prostate transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is UPK2 (Uroplakin 2), and among its related pathways/superpathways are Development ERBB-family signaling and Cytoskeletal Signaling. The drugs Vinblastine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and lymph node, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 72 Transitional cell carcinoma (TCC) also urothelial carcinoma (UCC), is a type of cancer that typically... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 334)
id Related Disease Score Top Affiliating Genes
1 infiltrating ureter transitional cell carcinoma 34.2 EGFR ERBB2
2 prostate transitional cell carcinoma 33.3 CDH1 KRT20 KRT7 TP53 UPK3A
3 prostate cancer 29.4 CDH1 EGFR ENO2 EPHB2 ERBB2 KRT18
4 lung cancer 27.4 CDH1 EGFR ENO2 ERBB2 KRT18 KRT20
5 sarcomatoid transitional cell carcinoma 12.3
6 ovary transitional cell carcinoma 12.1
7 invasive bladder transitional cell carcinoma 12.1
8 renal pelvis transitional cell carcinoma 12.1
9 ureter transitional cell carcinoma 12.1
10 fallopian tube transitional cell carcinoma 12.0
11 non-papillary transitional cell carcinoma of the bladder 12.0
12 bladder papillary transitional cell neoplasm 12.0
13 endometrial transitional cell carcinoma 12.0
14 urethra transitional cell carcinoma 12.0
15 kidney pelvis sarcomatoid transitional cell carcinoma 12.0
16 transitional cell carcinoma of the corpus uteri 12.0
17 bartholin's gland transitional cell carcinoma 12.0
18 urinary tract non-invasive transitional cell neoplasm 11.9
19 infiltrating renal pelvis transitional cell carcinoma 11.9
20 papillary transitional carcinoma 11.5
21 bladder urothelial carcinoma 11.2
22 bladder cancer, somatic 11.1
23 prostate cancer, hereditary, 2 10.9
24 prostate cancer, hereditary, 11 10.9
25 prostate cancer 1 10.9
26 fallopian tube carcinoma 10.9
27 urethral cancer 10.9
28 prostate cancer, hereditary, 12 10.9
29 prostate cancer, hereditary, 13 10.9
30 pediatric infratentorial ependymoma 10.9 EGFR TP53
31 brenner tumor of ovary 10.9
32 renal pelvis urothelial papilloma 10.9 CDH1 TP53
33 bladder tuberculosis 10.8 CDH1 ERBB2
34 congenital disorder of glycosylation, type if 10.8 ERBB2 TP53
35 tendon sheath lipoma 10.8 PTGS2 TP53
36 childhood teratoma of the ovary 10.8 CDH1 KRT20 UPK2
37 endocervicitis 10.8 ERBB2 TP53
38 esophagus squamous cell carcinoma 10.7 PTGS2 TP53 UPK2
39 skin sarcoma 10.7 EGFR ERBB2
40 penis squamous cell carcinoma 10.7 CDH1 EGFR ERBB2
41 her2-receptor negative breast cancer 10.7 EGFR ERBB2
42 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.7 CDH1 EGFR ERBB2
43 distal monosomy 7q36 10.7 EGFR ERBB2 TP53
44 comedo carcinoma 10.7 CDH1 EGFR ERBB2
45 integumentary system cancer 10.7 CDH1 EGFR TP53
46 villous adenocarcinoma 10.7 ERBB2 PTGS2 TP53
47 ureter adenocarcinoma 10.7 CDH1 EGFR ERBB2
48 subglottis verrucous carcinoma 10.7 EGFR ERBB2
49 pancreatic somatostatinoma 10.7 CDH1 EGFR TP53
50 mediastinum seminoma 10.7 TP53 UPK3A

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.93 BRINP1 CDH1 EGFR ENO2 EPHB2 ERBB2
2 digestive/alimentary MP:0005381 9.92 EGFR EPHB2 ERBB2 KRT8 MSH2 PTGS2
3 embryo MP:0005380 9.86 CDH1 EGFR ERBB2 KRT18 KRT8 PTGS2
4 neoplasm MP:0002006 9.5 CDH1 EGFR ERBB2 MSH2 PSCA PTGS2
5 renal/urinary system MP:0005367 9.17 KRT7 PTGS2 TP53 UPK2 UPK3A EGFR

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 266)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 2, Phase 3, Phase 1 865-21-4 13342 241903
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
5
Selenium Approved, Vet_approved Phase 3 7782-49-2
6
Valrubicin Approved Phase 3,Phase 2,Phase 1 56124-62-0 41744
7
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
12
Aminolevulinic acid Approved Phase 3 106-60-5 137
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
16
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
17
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
18
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
19
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 453 6251
20
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
21
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
22
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
23
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
24
Ethanol Approved Phase 3 64-17-5 702
25
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
26
Cephalexin Approved, Vet_approved Phase 3 15686-71-2 27447
27
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
28 Tocopherol Approved, Nutraceutical Phase 3
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
31
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
32
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
34
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262 389
35
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
36
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2 56-86-0 33032
37
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
38
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1
39
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
40
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
41
Fenretinide Investigational Phase 3 65646-68-6
42
Levulinic acid Experimental Phase 3 123-76-2 11579
43
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
44
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
45
Apaziquone Investigational Phase 3 114560-48-4 5813717
46 Antimitotic Agents Phase 2, Phase 3, Phase 1
47 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Antimetabolites Phase 3,Phase 2,Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 437)

id Name Status NCT ID Phase Drugs
1 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3 Cabazitaxel
2 Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Unknown status NCT01830231 Phase 2, Phase 3 Cabazitaxel;Vinflunine
3 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
4 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
5 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
6 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
7 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
8 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
9 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
10 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
11 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
12 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
13 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
14 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
15 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3 Cisplatin
16 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
17 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
18 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
19 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
20 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
21 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
22 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
23 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
24 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
25 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
26 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
27 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
28 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
29 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
30 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
31 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
32 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
33 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
34 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Recruiting NCT02853305 Phase 3 Cisplatin;Carboplatin;Gemcitabine
35 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
36 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3 Atezolizumab;Carboplatin;Gemcitabine;Cisplatin
37 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
38 A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010] Recruiting NCT02450331 Phase 3 Atezolizumab
39 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
40 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3 MitoGel™ instillations
41 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Recruiting NCT01993979 Phase 3 Chemotherapy
42 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
43 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
44 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
45 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
46 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3 Nanoxel®M;Mitomycin-C
47 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
48 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Active, not recruiting NCT02818725 Phase 3 Chemotherapy;panitumumab
49 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
50 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Genetic Tests for Transitional Cell Carcinoma

Anatomical Context for Transitional Cell Carcinoma

MalaCards organs/tissues related to Transitional Cell Carcinoma:

39
Kidney, Prostate, Lymph Node, Lung, Ovary, Testes, Endothelial

Publications for Transitional Cell Carcinoma

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 1212)
id Title Authors Year
1
Expression of receptor tyrosine kinase targets PDGFR-I^, VEGFR2 and KIT in canine transitional cell carcinoma. ( 28884928 )
2017
2
Radical Cystectomy and Cutaneous Ureterostomy in 4 Dogs with Trigonal Transitional Cell Carcinoma: Description of Technique and Case Series. ( 27911468 )
2017
3
High-grade transitional cell carcinoma masquerading as a xanthogranulomatous pyelonephritis and perinephric abscess. ( 28491170 )
2017
4
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). ( 28419193 )
2017
5
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. ( 28417194 )
2017
6
Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease. ( 28936147 )
2017
7
Transitional cell carcinoma involving graft kidney in a kidney transplant recipient: a case report. ( 28934936 )
2017
8
Association between chromosomal aberration of exfoliated bladder cells in the urine and oxidative stress in patients with bladder transitional cell carcinoma. ( 28693145 )
2017
9
Non-transitional cell carcinoma of the upper urinary tract: A case series among 305 cases at a tertiary urology institute. ( 28216943 )
2017
10
VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. ( 28098864 )
2017
11
Transitional Cell Carcinoma of Lacrimal Sac. ( 28582372 )
2017
12
Thrombus-like Tumor of Renal Cell Carcinoma Mimicking Transitional Cell Carcinoma of Kidney: A Case Report. ( 27896135 )
2017
13
Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. ( 28217972 )
2017
14
Huge Prostatic Utricle with Transitional Cell Carcinoma in an Adult. ( 28065811 )
2017
15
Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. ( 26945449 )
2017
16
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma. ( 28356972 )
2017
17
Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma. ( 28778323 )
2017
18
In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells. ( 28133930 )
2017
19
Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. ( 27878359 )
2017
20
The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma. ( 28194179 )
2017
21
Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy. ( 28506948 )
2017
22
Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target. ( 28871659 )
2017
23
ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell Carcinoma ( 28865418 )
2017
24
Transitional Cell Carcinoma in the Pediatric Patient: A Review of the Literature. ( 26802795 )
2016
25
Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin for Kidney Transplant Patients With Locally Advanced Transitional Cell Carcinoma: A Single-center Experience. ( 27569947 )
2016
26
Robot-Assisted Laparoscopic Nephroureterectomy for Transitional Cell Carcinoma of a Right Pelvic Kidney. ( 27579441 )
2016
27
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. ( 27855679 )
2016
28
Association of ABO blood types and clinicopathological features of ureteral transitional cell carcinoma in a single-center in China. ( 27461617 )
2016
29
Diagnostic value of strain elastography for differentiation between renal cell carcinoma and transitional cell carcinoma of kidney. ( 26880174 )
2016
30
Intrascotal metastasis of bladder transitional cell carcinoma as initial presentation of the disease. ( 28039727 )
2016
31
Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan. ( 26662954 )
2016
32
Transitional cell carcinoma with extension of the renal vein and IVC tumor thrombus: report of three cases and literature review. ( 28031042 )
2016
33
Posterior reversible encephalopathy syndrome mimicking brain metastases in a patient with metastatic transitional cell carcinoma. ( 27726296 )
2016
34
Demonstration of synchrotron x-ray phase contrast imaging computed tomography of infiltrative transitional cell carcinoma of the prostatic urethra in a dog. ( 27014719 )
2016
35
Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. ( 26810191 )
2016
36
Expression profile of SPACA5/Spaca5 in spermatogenesis and transitional cell carcinoma of the bladder. ( 27895724 )
2016
37
Choroidal Metastasis as an Unusual Initial Presentation of Transitional Cell Carcinoma of the Kidney. ( 27920701 )
2016
38
Re: Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. ( 27465469 )
2016
39
A pure primary transitional cell carcinoma of the ovary: A rare case report with literature review. ( 27127747 )
2016
40
Renal transitional cell carcinoma with bilateral ocular metastasis in a cat. ( 28491432 )
2016
41
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. ( 27228294 )
2016
42
WE-DE-BRA-03: Construction of An Ultrasound Guidance Platform for Image-Guided Radiotherapy with the Intent to Treat Transitional Cell Carcinoma. ( 28047007 )
2016
43
Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. ( 26781446 )
2016
44
Clinical experience of MRI in two dogs with muscle-invasive transitional cell carcinoma of the urinary bladder. ( 27149892 )
2016
45
Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. ( 27453656 )
2016
46
TOLERABILITY AND TUMOR RESPONSE OF A NOVEL LOW-DOSE PALLIATIVE RADIATION THERAPY PROTOCOL IN DOGS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER AND URETHRA. ( 26841125 )
2016
47
Penile metastasis from primary transitional cell carcinoma of the bladder sparing the urethra. ( 28096925 )
2016
48
Re: A Case of High-Grade Transitional Cell Carcinoma of the Bladder in a Pediatric Patient with Turner Syndrome. ( 27597108 )
2016
49
Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway. ( 26742010 )
2016
50
Thyroid metastasis of bladder transitional cell carcinoma. ( 27126668 )
2016

Variations for Transitional Cell Carcinoma

Copy number variations for Transitional Cell Carcinoma from CNVD:

7 (show top 50) (show all 92)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification ORAOV1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification C11orf76 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification FAM19A2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TM4SF3 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss SDFR1 Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss SDCCAG33 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss ZADH2 Urothelial cell carcinoma

Expression for Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for Transitional Cell Carcinoma

GO Terms for Transitional Cell Carcinoma

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 CDH1 ENO2 KRT18 KRT7 KRT8 PSCA
2 intermediate filament GO:0005882 9.26 KRT18 KRT20 KRT7 KRT8
3 apical plasma membrane GO:0016324 9.1 EGFR ERBB2 UPK1A UPK1B UPK2 UPK3A

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.62 KRT18 KRT20 KRT7 KRT8
2 cell surface receptor signaling pathway GO:0007166 9.55 EGFR ERBB2 IFNA2 UPK1A UPK1B
3 negative regulation of ERBB signaling pathway GO:1901185 9.48 EGFR ERBB2
4 determination of adult lifespan GO:0008340 9.46 MSH2 TP53
5 hepatocyte apoptotic process GO:0097284 9.43 KRT18 KRT8
6 cell morphogenesis GO:0000902 9.43 EGFR EPHB2 UPK3A
7 cornification GO:0070268 9.26 KRT18 KRT20 KRT7 KRT8
8 cell-cell adhesion GO:0098609 9.1 KRT18
9 positive regulation of synaptic plasticity GO:0031915 9.07 PTGS2
10 epithelial cell differentiation GO:0030855 8.92 UPK1A UPK1B UPK2 UPK3A

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.62 KRT18 KRT7 KRT8 UPK1B
2 protein binding GO:0005515 9.55 BRINP1 CDH1 EGFR ENO2 EPHB2 ERBB2
3 protein phosphatase binding GO:0019903 9.33 EGFR ERBB2 TP53
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 EGFR ERBB2
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHB2 ERBB2

Sources for Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....